Stay updated with breaking news from Regeneron Eylea. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Kodiak Sciences drug failed to beat a Regeneron Pharmaceuticals product in a key test in the wet form of age-related macular degeneration. The biotech says the failure is due to a subset of undertreated patients, but the results raise the stakes for the drug, its lead product candidate, in other eye diseases.
Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity) Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease. The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Unity shares were up about 9% in early trading Tuesday morning. The study of UBX1325 was conducted in pat...
Uber (UBER) – Uber lost 6 cents per share for its latest quarter, compared to expectations of a 54 cents a share loss. Revenue was below forecasts, however, and Uber indicated it would pay drivers more to get cars back in service as the economy rebounds. Uber fell 3.7% in premarket trading. Zynga (ZNGA) – Zynga earned 8 cents per share for the first quarter, a penny a share shy of estimates. The mobile game producer's revenue exceeded estimates and Zynga raised its full-year guidance on expectations of strong demand for its live gaming services. Its shares surged 5% in premarket action. R...
IN THE NEWS TODAY Moderna (MRNA) said its Covid vaccine was 96% effective in kids ages 12 to 17, according to early data released Thursday along with the company's mixed first-quarter earnings and revenue. Shares fell more than 9% in the premarket. (CNBC) Citing early data from another ongoing trial, Moderna said Wednesday a Covid booster shot generated a promising immune response against variants first identified in South Africa and Brazil. U.S. health officials said earlier Wednesday that highly contagious variants remain a "wild card" heading into the summer. (CNBC) The Biden administratio...
Published: Feb 12, 2021 By Kate Goodwin After announcing topline data from two identical Phase III trials, Roche’s Genentech has doubled down on data and is now Faricimab is an injectable treatment to maintain the vision of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). These are two of the leading causes of blindness with nAMD responsible for 90% of all blindness resulting from AMD. Genetech’s Lucentis was the first FDA-approved drug proven to restore sight in nAMD patients. Since 2006 it had been a game-chang...